http://www.epo.org/law-practice/case-law-appeals/recent/g020003ex1.html
Content reproduced from the Website of the European Patent Office as permitted by their terms of use.
European Case Law Identifier: | ECLI:EP:BA:2004:G000302.20040426 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 26 April 2004 | ||||||||
Case number: | G 0003/02 | ||||||||
Referral: | J 0010/98 | ||||||||
Application number: | 96908415.1 | ||||||||
IPC class: | C07K 14/35 C12N 15/81 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | A | ||||||||
Download and more information: |
|
||||||||
Title of application: | “New DNA molecules” “A DNA molecule for expression of bile salt-stimulated lipase (BSSL)” | ||||||||
Applicant name: | AstraZeneca AB | ||||||||
Opponent name: | – | ||||||||
Board: | EBA | ||||||||
Headnote: | The TRIPs Agreement does not entitle the applicant for a European patent application to claim priority from a first filing in a State which was not at the relevant dates a member of the Paris Convention but was a member of the WTO/TRIPs Agreement. | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | International applications – priorities from India Applicability of Article 87(5) EPC The position under the PCT The EPO not party to TRIPs Interpretation of Article 87 EPC – according to principles of public international law – in the light of obligations of Contracting States under TRIPs |
||||||||
Catchwords: |
– |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Summary of Facts and Submissions
for the fulltext please refer to G 0002/02